Abstract Background Bacterial persistence is a phenomenon where a subpopulation of bacteria can survive high concentrations of an active antibiotic in the absence of genotypic alterations. Persisters are associated with chronic and recurrent infections for pathogens including Pseudomonas aeruginosa. Evaluating persister profiles of FDC and C/T against P. aeruginosa is warranted as they are needed for difficult-to-treat infections. Methods Persisters were assessed using in vitro assays against 9 clinical P. aeruginosa isolates that developed resistance to C/T during therapy. Only index isolates (FDC and C/T-susceptible) were tested. Quantitative persister assays were performed using a stationary phase bacteria challenged with 10-fold MIC drug concentrations. Persisters were quantitated as the percent persisters at 24h and the log ratio (LR) difference in area under the curve for CFU (AUCFU) for each antibiotic alone referenced to control. Tolerance disk test (TDtest) was used to qualitatively detect persisters using full, half and quarter disks. Colonies within the inhibition zone after replacement of drug disk with a glucose disk indicated the presence of persister cells. Results Percent persisters at 24h ranged from 4.1% to 64.3% and 1.9% to 81.1% for FDC and C/T, respectively. Percent persisters at 24h was lower for FDC compared with C/T groups in 6 of the 9 tested isolates. 8 of the 9 isolates had higher reduction in LR for FDC groups (range, -0.6 to -0.9), indicating an overall higher and more rapid bacterial reduction in FDC groups compared to C/T (range, -0.3 to -0.9). For FDC, 5/9 tested isolates lacked regrowth after replacement with glucose disk suggesting no persistence per the TDtest. For C/T, only 3 isolates lacked persister formation. TDtest results were consistent across disk sizes and concordant with the quantitative assay. Conclusion These data link isolates that developed resistance to C/T with persister formation. FDC resulted in less bacterial persistence relative to C/T against 9 P. aeruginosa isolates. FDC’s siderophore mechanism may be advantageous over typical β-lactams via enhanced anti-persister activity. Clinical correlation of these findings are warranted as persisters can lead to antibiotic resistance and treatment failure. Disclosures Samantha Nicolau, PhD, Sanofi Pasteur: Full time research scientist Patricia J. Simner, PhD, Affinity Biosensors: Grant/Research Support|BD Diagnostics: Grant/Research Support|bioMérieux: Grant/Research Support|Entasis: Personal fees|GeneCapture: Personal Fees|Merck: Personal fees|OpGen Inc: Grant/Research Support|Qiagen: Grant/Research Support|Shionogi: Personal fees|T2 Biosystems: Grant/Research Support David P. Nicolau, PharmD, CARB-X: Grant/Research Support|Innoviva: Grant/Research Support|Innoviva: Honoraria|Merck: Advisor/Consultant|Merck: Grant/Research Support|Merck: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Pfizer: Honoraria|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Shionogi: Honoraria|Venatorx: Grant/Research Support Christian M. Gill, PharmD, Cepheid: Grant/Research Support|Entasis: Grant/Research Support|Everest Medicines: Grant/Research Support|Shionogi: Grant/Research Support
Read full abstract